Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia

References

• Rabinowitz J, Levine SZ, Haim R, Hafner H. The course of schizophrenia: progressive deterioration, amelioration or both? Schizophr Res. 2007;91(1–3):254–258. doi:10.1016/j.schres.2006.12.01317293084
   PubMed Web of Science ®Google Scholar
• Kahn RS, Sommer IE, Murray RM, et al. Schizophrenia. Nat Rev Dis Primers. 2015;1:15067. doi:10.1038/nrdp.2015.6727189524
   PubMed Web of Science ®Google Scholar
• Correll CU, Kishimoto T, Nielsen J, Kane JM. Quantifying clinical relevance in the treatment of schizophrenia. Clin Ther. 2011;33(12):B16–39. doi:10.1016/j.clinthera.2011.11.01622177377
   PubMed Web of Science ®Google Scholar
• Citrome L, Ketter TA. When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Int J Clin Pract. 2013;67(5):407–411. doi:10.1111/ijcp.1214223574101
   PubMed Web of Science ®Google Scholar
• Carbon M, Correll CU. Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin Neurosci. 2014;16(4):505–524.25733955
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry. 2006;67(3):453–460.16649833
   PubMed Web of Science ®Google Scholar
• Citrome L. New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia. Expert Rev Neurother. 2013;13(7):767–783. doi:10.1586/14737175.2013.81198423898849
   PubMed Web of Science ®Google Scholar
• Herings RM, Erkens JA. Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. Pharmacoepidemiol Drug Saf. 2003;12(5):423–424.12899119
   PubMed Web of Science ®Google Scholar
• Morken G, Widen JH, Grawe RW. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry. 2008;8:32.18447935
   PubMed Web of Science ®Google Scholar
• Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry. 2013;12(3):216–226. doi:10.1002/wps.2006024096780
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Zhu B, Faries DE, Furiak NM, Montgomery W. Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia. BMC Res Notes. 2009;2:6. doi:10.1186/1756-0500-2-619138402
   PubMedGoogle Scholar
• Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004;55(8):886–891. doi:10.1176/appi.ps.55.8.88615292538
   PubMed Web of Science ®Google Scholar
• Park EJ, Amatya S, Kim MS, et al. Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia. Arch Pharm Res. 2013;36(6):651–659. doi:10.1007/s12272-013-0105-723543652
   PubMed Web of Science ®Google Scholar
• Gopal S, Gassmann-Mayer C, Palumbo J, Samtani MN, Shiwach R, Alphs L. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia. Curr Med Res Opin. 2010;26(2):377–387. doi:10.1185/0300799090348277220001492
   PubMed Web of Science ®Google Scholar
• Davidson M, Emsley R, Kramer M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res. 2007;93(1–3):117–130. doi:10.1016/j.schres.2007.03.00317466492
   PubMed Web of Science ®Google Scholar
• Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res. 2007;90(1–3):147–161. doi:10.1016/j.schres.2006.09.01217092691
   PubMed Web of Science ®Google Scholar
• Kramer M, Simpson G, Maciulis V, et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2007;27(1):6–14. doi:10.1097/JCP.0b013e31802dda4a17224706
   PubMed Web of Science ®Google Scholar
• Schreiner A, Hargarter L, Hitschfield K, et al. Clinical effectiveness and resource utilization of paliperidone ER for schizophrenia: pharmacoepidemiologic International Longitudinal Antipsychotic Registry (PILAR). Curr Med Res Opin. 2014;30(7):1279–1289. doi:10.1185/03007995.2014.89863024597755
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceuticals, Inc. Invega Sustenna (Paliperidone Palmitate) Extended-Release Suspension. Prescribing Information. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2016 Accessed 35, 2018.
   Google Scholar
• Newton R, Hustig H, Lakshmana R, et al. Practical guidelines on the use of paliperidone palmitate in schizophrenia. Curr Med Res Opin. 2012;28(4):559–567. doi:10.1185/03007995.2012.66536222321007
   PubMed Web of Science ®Google Scholar
• Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2010;116(2–3):107–117. doi:10.1016/j.schres.2009.10.02619959339
   PubMed Web of Science ®Google Scholar
• Marcus SC, Zummo J, Pettit AR, Stoddard J, Doshi JA. Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge. J Manag Care Spec Pharm. 2015;21(9):754–768. doi:10.18553/jmcp.2015.21.9.75426308223
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Kim E, Bermak J, Turkoz I, Gopal S, Berwaerts J. Does half-life matter after antipsychotic discontinuation? A relapse comparison in schizophrenia with 3 different formulations of paliperidone. J Clin Psychiatry. 2017;78(7):e813–e820. doi:10.4088/JCP.16m1130828640988
   PubMed Web of Science ®Google Scholar
• Zhang F, Si T, Chiou CF, et al. Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia. Neuropsychiatr Dis Treat. 2015;11:657–668. doi:10.2147/NDT.S7777825792835
   PubMed Web of Science ®Google Scholar
• Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M, Hough D. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. J Psychopharmacol. 2011;25(5):685–697. doi:10.1177/026988111037281720615933
   PubMed Web of Science ®Google Scholar
• Pandina GJ, Lindenmayer JP, Lull J, et al. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol. 2010;30(3):235–244. doi:10.1097/JCP.0b013e3181dd310320473057
   PubMed Web of Science ®Google Scholar
• Emsley R, Parellada E, Bioque M, Herrera B, Hernando T, Garcia-Dorado M. Real-world data on paliperidone palmitate for the treatment of schizophrenia and other psychotic disorders: a systematic review of randomized and nonrandomized studies. Int Clin Psychopharmacol. 2018;33(1):15–33. doi:10.1097/YIC.000000000000019528817397
   PubMed Web of Science ®Google Scholar
• Fu DJ, Turkoz I, Simonson RB, et al. Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder. J Clin Psychiatry. 2015;76(3):253–262. doi:10.4088/JCP.14m0941625562685
   PubMed Web of Science ®Google Scholar
• Fu DJ, Turkoz I, Walling D, Lindenmayer JP, Schooler NR, Alphs L. Paliperidone palmitate once-monthly maintains improvement in functioning domains of the personal and social performance scale compared with placebo in subjects with schizoaffective disorder. Schizophr Res. 2018;192:185–193. doi:10.1016/j.schres.2017.04.00428454922
   PubMed Web of Science ®Google Scholar
• Samtani MN, Nandy P, Ravenstijn P, et al. Prospective dose selection and acceleration of paliperidone palmitate 3-month formulation development using a pharmacometric bridging strategy. Br J Clin Pharmacol. 2016;82(5):1364–1370. doi:10.1111/bcp.1305027333588
   PubMed Web of Science ®Google Scholar
• Gopal S, Vermeulen A, Nandy P, et al. Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia. Curr Med Res Opin. 2015;31(11):2043–2054. doi:10.1185/03007995.2015.108584926306819
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceuticals, Inc. Invega Trinza (Paliperidone Palmitate) Extended-Release Suspension. Prescribing Information. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2017 Accessed 35, 2018.
   Google Scholar
• Berwaerts J, Liu Y, Gopal S, et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2015;72(8):830–839. doi:10.1001/jamapsychiatry.2015.024125820612
   PubMed Web of Science ®Google Scholar
• Savitz AJ, Xu H, Gopal S, et al. Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority study. Int J Neuropsychopharmacol. 2016;19:7. doi:10.1093/ijnp/pyw018
   Web of Science ®Google Scholar
• Citrome L, Ketter TA. NNT and NNH remain helpful in evidence-based medicine. Br J Psychiatry. 2016;209(3):262–263. doi:10.1192/bjp.209.3.262b
   Web of Science ®Google Scholar
• Citrome L, Ketter TA, Cucchiaro J, Loebel A. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord. 2014;155:20–27. doi:10.1016/j.jad.2013.10.04024246116
   PubMed Web of Science ®Google Scholar
• Gopal S, Berwaerts J, Nuamah I, et al. Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia. Neuropsychiatr Dis Treat. 2011;7:93–101. doi:10.2147/NDT.S1717721552311
   PubMed Web of Science ®Google Scholar
• Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ. 1999;319(7223):1492–1495.10582940
   PubMed Web of Science ®Google Scholar
• Mathews M, Nuamah I, Savitz A, Gopal S. Efficacy and safety of paliperidone palmitate 3-month formulation vs placebo for relapse prevention of schizophrenia: treatment effect using a number needed to treat analysis. Biol Psychiatry. 2017;81(10):S350–S351. doi:10.1016/j.biopsych.2017.02.592
   Web of Science ®Google Scholar
• Faraone SV. Interpreting estimates of treatment effects: implications for managed care. P T. 2008;33(12):700–711.19750051
   PubMedGoogle Scholar
• Andreasen NC, Carpenter WT Jr., Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162(3):441–449. doi:10.1176/appi.ajp.162.3.44115741458
   PubMed Web of Science ®Google Scholar
• Kawata AK, Revicki DA. Psychometric properties of the personal and social performance scale (PSP) among individuals with schizophrenia living in the community. Qual Life Res. 2008;17(10):1247–1256. doi:10.1007/s11136-008-9400-z18855124
   PubMed Web of Science ®Google Scholar
• Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and occupational functioning assessment scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000;101(4):323–329.10782554
   PubMed Web of Science ®Google Scholar
• van Os J, Burns T, Cavallaro R, et al. Standardized remission criteria in schizophrenia. Acta Psychiatr Scand. 2006;113(2):91–95. doi:10.1111/j.1600-0447.2005.00659.x16423159
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276.3616518
   PubMed Web of Science ®Google Scholar
• Gopal S, Xu H, McQuarrie K, et al. Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies. NPJ Schizophr. 2017;3(1):23. doi:10.1038/s41537-017-0025-528751663
   PubMed Web of Science ®Google Scholar
• van Wijngaarden B, Schene AH, Koeter M, et al.Caregiving in schizophrenia: development, internal consistency and reliability of the involvement evaluation questionnaire–European version. EPSILON study 4. European psychiatric services: inputs linked to outcome domains and needs. Br J Psychiatry Suppl. 2000;(39):s21–27. doi:10.1192/bjp.177.39.s2110945074
   PubMedGoogle Scholar
• Si T, Zhang K, Tang J, et al. Efficacy and safety of flexibly dosed paliperidone palmitate in Chinese patients with acute schizophrenia: an open-label, single-arm, prospective, interventional study. Neuropsychiatr Dis Treat. 2015;11:1483–1492. doi:10.2147/NDT.S8176026150719
   PubMed Web of Science ®Google Scholar
• Hargarter L, Bergmans P, Cherubin P, et al. Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia. Expert Opin Pharmacother. 2016;17(8):1043–1053. doi:10.1080/14656566.2016.117469227042990
   PubMed Web of Science ®Google Scholar
• Li H, Li Y, Feng Y, et al. Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL study. Neuropsychiatr Dis Treat. 2018;14:1107–1117. doi:10.2147/NDT.S15739929731633
   PubMed Web of Science ®Google Scholar
• Li H, Turkoz I, Zhang F. Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study. Neuropsychiatr Dis Treat. 2016;12:15–24. doi:10.2147/NDT.S8365126730193
   PubMed Web of Science ®Google Scholar
• Nasrallah HA, Gopal S, Gassmann-Mayer C, et al. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology. 2010;35(10):2072–2082. doi:10.1038/npp.2010.7920555312
   PubMed Web of Science ®Google Scholar
• Pandina G, Lane R, Gopal S, et al. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(1):218–226. doi:10.1016/j.pnpbp.2010.11.00821092748
   PubMed Web of Science ®Google Scholar
• Mathews M, Gopal S, Singh A, Gogate J, Edward Kim PK. Comparison of paliperidone palmitate 3-month and paliperidone palmitate 1-month formulation for negative symptoms in schizophrenia: A phase 3 non-inferiority study. Schizophr Bull. 2018;44(Suppl 1):S311. doi:10.1093/schbul/sby017.761
   Web of Science ®Google Scholar
• Remington G, Foussias G, Fervaha G, et al. Treating negative symptoms in schizophrenia: an update. Curr Treat Options Psychiatry. 2016;3:133–150. doi:10.1007/s40501-016-0075-827376016
   PubMedGoogle Scholar
• Savitz AJ, Xu H, Gopal S, Nuamah I, Hough D, Mathews M. Paliperidone palmitate 3-month treatment results in symptomatic remission in patients with schizophrenia: a randomized, multicenter, double-blind, and noninferiority study. Int Clin Psychopharmacol. 2017;32(6):329–336. doi:10.1097/YIC.000000000000019028806194
   PubMed Web of Science ®Google Scholar
• Anderson JP, Icten Z, Alas V, Benson C, Joshi K. Comparison and predictors of treatment adherence and remission among patients with schizophrenia treated with paliperidone palmitate or atypical oral antipsychotics in community behavioral health organizations. BMC Psychiatry. 2017;17(1):346. doi:10.1186/s12888-017-1489-629047368
   PubMed Web of Science ®Google Scholar
• Brown B, Turkoz I, Mancevski B, Mathews M. PM411. evaluation of paliperidone palmitate long-acting injectable therapy by duration of illness in patients with schizophrenia. Int J Neuropsychopharmacol. 2016;19(Suppl 1):49. doi:10.1093/ijnp/pyw041.411
   Google Scholar
• Chirila C, Nuamah I, Woodruff K. Health care resource use analysis of paliperidone palmitate 3 month injection from two phase 3 clinical trials. Curr Med Res Opin. 2017;33(6):1083–1090. doi:10.1080/03007995.2017.130014428277864
   PubMed Web of Science ®Google Scholar
• Srihari G, Haiyan X, Adam S, et al. PM511. determinants of caregiver burden in family carers of asian patients with schizophrenia treated with paliperidone palmitate 3-monthly injectable. Int J Neuropsychopharmacol. 2016;19(Suppl_1):85–86. doi:10.1093/ijnp/pyw041.511
   Google Scholar
• Zhao J, Li L, Shi J, et al. Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study. Neuropsychiatr Dis Treat. 2017;13:2045–2056. doi:10.2147/NDT.S13122428814873
   PubMed Web of Science ®Google Scholar
• Katz EG, Hauber B, Gopal S, et al. Physician and patient benefit-risk preferences from two randomized long-acting injectable antipsychotic trials. Patient Prefer Adherence. 2016;10:2127–2139. doi:10.2147/PPA.S11417227799749
   PubMed Web of Science ®Google Scholar
• Nash A, Turkoz I, Savitz A, Maju Mathews KE. Predictors of Achieving Remission in Schizophrenia Patients Treated with Paliperidone Palmitate 3-Month Formulation. 30th Annual Psych Congress; 9 16-19, 2017; New Orleans, Louisiana.
   Google Scholar
• Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28–37.
   PubMedGoogle Scholar
• Bossie CA, Fu DJ, Sliwa JK, Ma YW, Alphs L. Tolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trial. Ther Adv Psychopharmacol. 2011;1(4):111–124. doi:10.1177/204512531141300623983935
   PubMedGoogle Scholar
• Kramer M, Litman R, Hough D, et al. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol. 2010;13(5):635–647. doi:10.1017/S146114570999098819941696
   PubMed Web of Science ®Google Scholar
• Alphs L, Bossie CA, Sliwa JK, Ma YW, Turner N. Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial. Ann Gen Psychiatry. 2011;10(1):12. doi:10.1186/1744-859X-10-1221481243
   PubMed Web of Science ®Google Scholar
• Mathews M, Nuamah I, Savitz A, et al. PM410. comparison of 3-monthly versus 1-monthly paliperidone palmitate for time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia. Int J Neuropsychopharmacol. 2016;19(Suppl 1):49. doi:10.1093/ijnp/pyw041.410
   Google Scholar
• Elefant E, Sliwa JK, Savitz A, et al. PM386. an assessment of injection site reactions and injection site pain of once-every one month and three-month long-acting injectable formulations of paliperidone palmitate. Int J Neuropsychopharmacol. 2016;19(Suppl 1):41. doi:10.1093/ijnp/pyw041.386
   Google Scholar
• Kern Sliwa J, Savitz A, Nuamah I, et al. An assessment of injection site reaction and injection site pain of 1-month and 3-month long-acting injectable formulations of paliperidone palmitate. Perspect Psychiatr Care. 2018. doi:10.1111/ppc.12267
   Web of Science ®Google Scholar
• Savitz AJ, Xu H, Gopal S, et al. Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study. Neuropsychiatr Dis Treat. 2017;13:2193–2207. doi:10.2147/NDT.S13428728860777
   PubMed Web of Science ®Google Scholar
• Bruijnzeel D, Suryadevara U, Tandon R. Antipsychotic treatment of schizophrenia: an update. Asian J Psychiatr. 2014;11:3–7.25216917
   PubMedGoogle Scholar
• Carbon M, Correll CU. Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. CNS Spectr. 2014;19(Suppl 1):38–52;quiz 35–37, 53.
   Google Scholar
• Kane JM. Improving patient outcomes in schizophrenia: achieving remission, preventing relapse, and measuring success. J Clin Psychiatry. 2013;74(9):e18.24107769
   PubMed Web of Science ®Google Scholar
• Correll CU, Citrome L, Haddad PM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016;77(suppl 3):1–24.27732772
   PubMed Web of Science ®Google Scholar
• Rauch AS, Fleischhacker WW. Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective. CNS Drugs. 2013;27(8):637–652.23780619
   PubMed Web of Science ®Google Scholar
• Haddad PM, Kishimoto T, Correll CU, Kane JM. Ambiguous findings concerning potential advantages of depot antipsychotics: in search of clinical relevance. Curr Opin Psychiatry. 2015;28(3):216–221.25785710
   PubMed Web of Science ®Google Scholar
• Kane JM, Kishimoto T, Correll CU. Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. J Clin Epidemiol. 2013;66(8 Suppl):S37–41.23849151
   PubMed Web of Science ®Google Scholar
• Kishi T, Matsunaga S, Iwata N. Mortality risk associated with long-acting injectable antipsychotics: a systematic review and meta-analyses of randomized controlled trials. Schizophr Bull. 2016;42(6):1438–1445.27086079
   PubMed Web of Science ®Google Scholar
• Kishi T, Oya K, Iwata N. Long-acting injectable antipsychotics for the prevention of relapse in patients with recent-onset psychotic disorders: A systematic review and meta-analysis of randomized controlled trials. Psychiatry Res. 2016;246:750–755.27863801
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Robenzadeh A, Leucht C, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull. 2014;40(1):192–213.23256986
   PubMed Web of Science ®Google Scholar
• Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. Oral versus depot antipsychotic drugs for schizophrenia–a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res. 2011;127(1–3):83–92.21257294
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Hagi K, Nitta M, et al. Effectiveness of long-acting injectable vs oral antipsychotics in patients with schizophrenia: a meta-analysis of prospective and retrospective cohort studies. Schizophr Bull. 2018;44(3):603–619.29868849
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2013;74(10):957–965.24229745
   PubMed Web of Science ®Google Scholar
• Misawa F, Kishimoto T, Hagi K, Kane JM, Correll CU. Safety and tolerability of long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics. Schizophr Res. 2016;176(2–3):220–230.27499361
   PubMed Web of Science ®Google Scholar
• Taipale H, Mittendorfer-Rutz E, Alexanderson K, et al. Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia. Schizophr Res. 2017;197:271–280.
   PubMed Web of Science ®Google Scholar
• De Hert M, Sermon J, Geerts P, Vansteelandt K, Peuskens J, Detraux J. The use of continuous treatment versus placebo or intermittent treatment strategies in stabilized patients with schizophrenia: a systematic review and meta-analysis of randomized controlled trials with first- and second-generation antipsychotics. CNS Drugs. 2015;29(8):637–658.26293744
   PubMed Web of Science ®Google Scholar
• Zhornitsky S, Stip E. Oral versus long-acting injectable antipsychotics in the treatment of schizophrenia and special populations at risk for treatment nonadherence: a systematic review. Schizophr Res Treatment. 2012;2012:407171.22966436
   PubMedGoogle Scholar
• Bioque M, Bernardo M. The current data on the 3-month paliperidone palmitate formulation for the treatment of schizophrenia. Expert Opin Pharmacother. 2018;19(14):1623–1629.30244607
   PubMed Web of Science ®Google Scholar
• Ostuzzi G, Papola D, Gastaldon C, Barbui C. New EMA report on paliperidone 3-month injections: taking clinical and policy decisions without an adequate evidence base. Epidemiol Psychiatr Sci. 2017;26(3):231–233.28004623
   PubMed Web of Science ®Google Scholar
• J C. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale (NJ): Erlbaum;1988.
   Google Scholar
• Kraemer HC, Kupfer DJ. Size of treatment effects and their importance to clinical research and practice. Biol Psychiatry. 2006;59(11):990–996.16368078
   PubMed Web of Science ®Google Scholar
• Andreasen NC, Flaum M, Swayze VW 2nd, Tyrrell G, Arndt S. Positive and negative symptoms in schizophrenia. A critical reappraisal. Arch Gen Psychiatry. 1990;47(7):615–621.2360855
   PubMed Web of Science ®Google Scholar
• Andreasen NC, Olsen S. Negative v positive schizophrenia. Definition and validation. Arch Gen Psychiatry. 1982;39(7):789–794.7165478
   PubMed Web of Science ®Google Scholar
• Buchanan RW. Persistent negative symptoms in schizophrenia: an overview. Schizophr Bull. 2007;33(4):1013–1022.17099070
   PubMed Web of Science ®Google Scholar
• Lee J, Takeuchi H, Fervaha G, et al. Subtyping schizophrenia by treatment response: antipsychotic development and the central role of positive symptoms. Can J Psychiatry. 2015;60(11):515–522.26720509
   PubMed Web of Science ®Google Scholar
• Arango C, Garibaldi G, Marder SR. Pharmacological approaches to treating negative symptoms: a review of clinical trials. Schizophr Res. 2013;150(2–3):346–352.23938176
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP, Khan A, Iskander A, Abad MT, Parker B. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. J Clin Psychiatry. 2007;68(3):368–379.17388705
   PubMed Web of Science ®Google Scholar
• Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31–41.19058842
   PubMed Web of Science ®Google Scholar
• Mossaheb N, Kaufmann RM. Role of aripiprazole in treatment-resistant schizophrenia. Neuropsychiatr Dis Treat. 2012;8:235–244. doi:10.2147/NDT.S1383022701324
   PubMed Web of Science ®Google Scholar
• Canuso CM, Bossie CA, Turkoz I, Alphs L. Paliperidone extended-release for schizophrenia: effects on symptoms and functioning in acutely ill patients with negative symptoms. Schizophr Res. 2009;113(1):56–64. doi:10.1016/j.schres.2009.05.02119560322
   PubMed Web of Science ®Google Scholar
• Schreiner A, Bergmans P, Cherubin P, Hargarter L. The effect of long-acting paliperidone palmitate once-monthly on negative and depressive symptoms in patients with schizophrenia switched from previous unsuccessful treatment with oral aripiprazole. Ther Adv Psychopharmacol. 2017;7(2):59–65. doi:10.1177/204512531667301228255435
   PubMed Web of Science ®Google Scholar
• Beitinger R, Lin J, Kissling W, Leucht S. Comparative remission rates of schizophrenic patients using various remission criteria. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(7):1643–1651. doi:10.1016/j.pnpbp.2008.06.00818616969
   PubMed Web of Science ®Google Scholar
• Shamsi S, Lau A, Lencz T, et al. Cognitive and symptomatic predictors of functional disability in schizophrenia. Schizophr Res. 2011;126(1–3):257–264. doi:10.1016/j.schres.2010.08.00720828991
   PubMed Web of Science ®Google Scholar
• Rajji TK, Miranda D, Bh M. Cognition, function, and disability in patients with schizophrenia: a review of longitudinal studies. Can J Psychiatry Revue Canadienne De Psychiatr. 2014;59(1):13–17. doi:10.1177/070674371405900104
   PubMed Web of Science ®Google Scholar
• Harvey PD, Bellack AS. Toward a terminology for functional recovery in schizophrenia: is functional remission a viable concept? Schizophr Bull. 2009;35(2):300–306. doi:10.1093/schbul/sbn17119126634
   PubMed Web of Science ®Google Scholar
• Valencia M, Fresan A, Barak Y, Juarez F, Escamilla R, Saracco R. Predicting functional remission in patients with schizophrenia: a cross-sectional study of symptomatic remission, psychosocial remission, functioning, and clinical outcome. Neuropsychiatr Dis Treat. 2015;11:2339–2348. doi:10.2147/NDT.S8733526396518
   PubMed Web of Science ®Google Scholar
• Awad AG, Voruganti LN. The burden of schizophrenia on caregivers: a review. PharmacoEconomics. 2008;26(2):149–162. doi:10.2165/00019053-200826020-0000518198934
   PubMed Web of Science ®Google Scholar
• Yazici E, Karabulut Ü, Yildiz M, et al. Burden on caregivers of patients with schizophrenia and related factors. Nöro Psikiyatri Arsivi. 2016;53(2):96–101. doi:10.5152/npa.2015.996328360779
   PubMedGoogle Scholar
• Biagi E, Capuzzi E, Colmegna F, et al. Long-acting injectable antipsychotics in schizophrenia: literature review and practical perspective, with a focus on aripiprazole once-monthly. Adv Ther. 2017;34(5):1036–1048. doi:10.1007/s12325-017-0507-x28382557
   PubMed Web of Science ®Google Scholar
• Mancevski B, Gogate J, Ashcroft K, Tardieu K, Kim E. Correlation of Caregiver Burden and Baseline Characteristics of Caregivers and Patients in Their Care with Recent-Onset Psychosis: the FIRST Study. Psychopharmacol Bull. 2017;47(3):17–25.28839336
   PubMedGoogle Scholar
• Fe Bravo-Ortiz M, Gutierrez-Casares JR, Rodriguez-Morales A, Garcia MA, Hidalgo-Borrajo R. Influence of type of treatment on the well-being of Spanish patients with schizophrenia and their caregivers. Int J Psychiatry Clin Pract. 2011;15(4):286–295. doi:10.3109/13651501.2011.60846922122003
   PubMed Web of Science ®Google Scholar
• Carr CN, Hall CP, Roche-Desilets JE, Burant CJ, Fuller MA. Evaluation of adherence in patients prescribed long-acting injectable antipsychotics: A comparison of biweekly versus monthly administered neuroleptics. Ment Health Clin. 2016;6(5):248–253. doi:10.9740/mhc.2016.09.24829955478
   PubMedGoogle Scholar
• Meyers KJ, Upadhyaya HP, Landry JL, et al. Postinjection delirium/sedation syndrome in patients with schizophrenia receiving olanzapine long-acting injection: results from a large observational study. BJPsych Open. 2017;3(4):186–192. doi:10.1192/bjpo.bp.116.00438228811926
   PubMed Web of Science ®Google Scholar
• Gentile S. Adverse effects associated with second-generation antipsychotic long-acting injection treatment: a comprehensive systematic review. Pharmacotherapy. 2013;33(10):1087–1106. doi:10.1002/phar.131323776129
   PubMed Web of Science ®Google Scholar
• Leucht S, Davis JM. Second-generation antipsychotics and quality of life in schizophrenia. Lancet Psychiatry. 2016;3(8):694–695. doi:10.1016/S2215-0366(16)30093-127265549
   PubMed Web of Science ®Google Scholar
• Ho C, Jones S. Three-Month Injectable Paliperidone Palmitate for the Treatment of Adults with Schizophrenia: A Review of Clinical Effectiveness, Safety, and Guidelines. Ottawa (ON); Canadian Agency for Drugs and Technologies in Health2017.
   Google Scholar
• Gentile S. Safety concerns associated with second-generation antipsychotic long-acting injection treatment. A systematic update. Horm Mol Biol Clin Investig. 2017. doi:10.1515/hmbci-2017-0004
   Web of Science ®Google Scholar
• Parellada E, Bioque M. Barriers to the Use of long-acting injectable antipsychotics in the management of schizophrenia. CNS Drugs. 2016;30(8):689–701. doi:10.1007/s40263-016-0350-727255405
   PubMed Web of Science ®Google Scholar